A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a)

Inclusion Criteria: * Adult patients, \>/= 18 years of age * Chronic hepatitis C, genotype 1 * Treatment-naïve or patients who relapsed or failed to respond to previous combination therapy with interferon and ribavirin * Detectable HCV-RNA * Fertile males and females of child-bearing potential must agree to use two forms of contraception during treatment and for 6 months after treatment end Exclusion Criteria: * Pregnant or breast-feeding women * Male partners of pregnant women * History or evidence of a medical condition associated with chronic liver disease other than HCV * Co-infection with active hepatitis A, hepatitis B and/or HIV virus * Hepatocellular carcinoma * History or evidence of oesophageal varices or other conditions consistent with decompensated liver disease * Anemia * Any patient with increased baseline risk for anemia (e.g. thalassemia, spherocyctosis, history of GI bleeding) * History or evidence of significant cardiovascular disease * Kidney disease * Severe retinopathy * History of severe psychiatric disease, especially depression * Therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) \</= 6 months prior to first dose of study drug